Tom Leemhuis
About
Tom Leemhuis is a scholar working on Hematology, Oncology and Immunology.
According to data from OpenAlex, Tom Leemhuis has authored 18 papers receiving a total of 462 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 8 papers in Oncology and 8 papers in Immunology. Recurrent topics in Tom Leemhuis's work include Hematopoietic Stem Cell Transplantation (9 papers), Cytomegalovirus and herpesvirus research (4 papers) and Acute Myeloid Leukemia Research (3 papers). Tom Leemhuis is often cited by papers focused on Hematopoietic Stem Cell Transplantation (9 papers), Cytomegalovirus and herpesvirus research (4 papers) and Acute Myeloid Leukemia Research (3 papers). Tom Leemhuis collaborates with scholars based in United States, France and Israel. Tom Leemhuis's co-authors include Elie G. Hanania, K Atkinson, Michael Grimley, Stella M. Davies, Sharat Chandra, Laura Johnston, J Brandt, Jack Bleesing, Edwin Walker and Keith Stockerl‐Goldstein and has published in prestigious journals such as AIDS, American Journal of Transplantation and Cytometry.
In The Last Decade
Tom Leemhuis
17 papers receiving 448 citations
Peers
Tom Leemhuis
Noemi F. Pereira Brazil
Duy T. Le United States
Yoshinori Ohno Japan
Michael K. Schowalter United States
Anja Troeger Germany
E. Hild United States
Emilia Salzmann‐Manrique Germany
Moreno Festuccia Italy
Галина Новичкова Russia
Heidrun Boztug Austria
Citations per year, relative to Tom Leemhuis Tom Leemhuis (= 1×)
peers
Noemi F. Pereira
Countries citing papers authored by Tom Leemhuis
Since
Specialization
Citations
This map shows the geographic impact of Tom Leemhuis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Leemhuis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Leemhuis more than expected).
Fields of papers citing papers by Tom Leemhuis
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Tom Leemhuis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Leemhuis. The network helps show where Tom Leemhuis may publish in the future.
Co-authorship network of co-authors of Tom Leemhuis
This figure shows the co-authorship network connecting the top 25 collaborators of Tom Leemhuis. A scholar is included among the top collaborators of Tom Leemhuis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Leemhuis. Tom Leemhuis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Grimley, Michael, Tom Leemhuis, José A. Cancelas, et al.. (2024). Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant. American Journal of Transplantation. 24(9). 1634–1643.
2.
Rubinstein, Jeremy D., Carolyn Lutzko, Tom Leemhuis, et al.. (2021). Scheduled Donor-Derived Viral Specific T-Cells for Prophylaxis Against Double Stranded DNA Viral Infection after Pediatric Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. 27(3). S87–S88.
3.
Rubinstein, Jeremy D., Xiang Zhu, Carolyn Lutzko, et al.. (2020). Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy. Blood Advances. 4(14). 3252–3257.
4.
Rubinstein, Jeremy D., Karen Burns, Michael J. Absalon, et al.. (2019). EBV‐directed viral‐specific T‐lymphocyte therapy for the treatment of EBV‐driven lymphoma in two patients with primary immunodeficiency and DNA repair defects. Pediatric Blood & Cancer. 67(3).
5.
Chandra, Sharat, Jack Bleesing, Michael B. Jordan, et al.. (2018). Post-Transplant CD34+ Selected Stem Cell “Boost” for Mixed Chimerism after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Children and Young Adults with Primary Immune Deficiencies. Biology of Blood and Marrow Transplantation. 24(7). 1527–1529.
6.
Leemhuis, Tom, et al.. (2018). Increased CD34 Cell Dose is Associated with Rapid Immune Reconstitution after HSCT in Patients with Fanconi Anemia. Biology of Blood and Marrow Transplantation. 24(3). S435–S436.
7.
Mehta, Parinda A., Jamie Wilhelm, Tom Leemhuis, et al.. (2018). What's Next after Elimination of Radiation?—A “Risk-Adjusted” Cytoreduction for Patients with Fanconi Anemia (FA) Undergoing Transplantation. Biology of Blood and Marrow Transplantation. 24(3). S119–S119.
8.
Chandra, Sharat, Jack Bleesing, Michael B. Jordan, et al.. (2018). Post-Transplant CD34+ Selected Stem Cell “Boost” as Intervention for Mixed Chimerism Following Reduced Intensity Conditioning HSCT in Children and Young Adults with Primary Immune Deficiencies. Biology of Blood and Marrow Transplantation. 24(3). S433–S434.
9.
Marsh, Rebecca, Marepalli B. Rao, Parinda A. Mehta, et al.. (2015). Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen. Biology of Blood and Marrow Transplantation. 21(8). 1460–1470.
10.
Marsh, Rebecca, Marepalli B. Rao, Parinda A. Mehta, et al.. (2015). Alemtuzumab, Fludarabine, and Melphalan Reduced Intensity Conditioning Hematopoietic Cell Transplantation: Experience in over 200 Pediatric and Young Adult Patients with Primary Immune Deficiency, Metabolic, and Marrow Failure Disorders. Biology of Blood and Marrow Transplantation. 21(2). S232–S232.
11.
Mehta, Parinda A., Stella M. Davies, Kasiani C. Myers, et al.. (2015). Chemotherapy-Only Preparative Regimen for Alternative Donor Hematopoietic Cell Transplantation for Patients with Fanconi Anemia (FA): Results of a Multi-Institutional Study. Biology of Blood and Marrow Transplantation. 21(2). S104–S105.
12.
Marsh, Rebecca, Mi‐Ok Kim, Chunyan Liu, et al.. (2013). An Intermediate Alemtuzumab Schedule Reduces the Incidence of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis. Biology of Blood and Marrow Transplantation. 19(11). 1625–1631.
13.
Negrin, Robert S., K Atkinson, Tom Leemhuis, et al.. (2000). Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. Biology of Blood and Marrow Transplantation. 6(3). 262–271.
14.
Michallet, Mauricette, Thierry Philip, Irène Philip, et al.. (2000). Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma. Experimental Hematology. 28(7). 858–870.
15.
Schnizlein‐Bick, Carol, et al.. (1992). Incidence of HIV infection in monocyte subpopulations characterized by CD4 and HLA-DR surface density. AIDS. 6(2). 151–156.
16.
Srour, Edward F., Tom Leemhuis, J Brandt, Koen van Besien, & Robert S. Hoffman. (1991). Simultaneous use of Rhodamine 123, phycoerythrin, Texas red, and allophycocyanin for the isolation of human hematopoietic progenitor cells. Cytometry. 12(2). 179–183.
17.
Leemhuis, Tom, et al.. (1990). Cytolytic activity of human natural killer cell subpopulations isolated by four‐color immunofluorescence flow cytometric cell sorting. Cytometry. 11(3). 442–446.
18.
Geißler, Klaus, Guido Tricot, Tom Leemhuis, Edwin Walker, & Hal E. Broxmeyer. (1989). Differentiation-inducing effect of recombinant human tumor necrosis factor alpha and gamma-interferon in vitro on blast cells from patients with acute myeloid leukemia and myeloid blast crisis of chronic myeloid leukemia.. PubMed. 49(11). 3057–62.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Noemi F. Pereira Breakdown of academic impact, for papers by Duy T. Le Breakdown of academic impact, for papers by Yoshinori Ohno Breakdown of academic impact, for papers by Michael K. Schowalter Breakdown of academic impact, for papers by Anja Troeger Breakdown of academic impact, for papers by E. Hild Breakdown of academic impact, for papers by Emilia Salzmann‐Manrique Breakdown of academic impact, for papers by Moreno Festuccia Breakdown of academic impact, for papers by Галина Новичкова Breakdown of academic impact, for papers by Heidrun Boztug